Literature DB >> 31189782

Production of the herb Ruta chalepensis L. expressing amyloid β-GFP fusion protein.

Taiji Yoshida1, Yuichiro Watanabe2, Shoichi Ishiura3.   

Abstract

The herb Ruta chalepensis L. exhibits medical effects, such as anti-inflammatory, central nervous system depressant, and antipyretic activities. However, a genetic transformation method has not yet been developed for this species. In this paper, a simple and efficient tissue culture and genetic transformation system for R. chalepensis is reported. An amyloid β-peptide (Aβ) gene, which is considered to be a causative agent of Alzheimer's disease (AD), fused with green-fluorescent protein (GFP), was introduced into R. chalepensis. When the leaves of R. chalepensis expressing Aβ-GFP were administered orally to C57BL/6J mice, serum anti-Aβ antibody titers of several mice were elevated without the use of an adjuvant. These results indicated that an oral vaccine against AD using R. chalepensis may be feasible. R. chalepensis is rich in bioactive compounds that may have synergistic effects with the vaccine for AD. Plant-derived vaccines are safer and cheaper than those produced from animal cells or microbes, because plants can serve as biofactories at low cost and with high biosynthetic capacity.

Entities:  

Keywords:  Alzheimer’s disease; Ruta chalepensis L; amyloid β-peptide; vaccine

Mesh:

Substances:

Year:  2019        PMID: 31189782      PMCID: PMC6751298          DOI: 10.2183/pjab.95.021

Source DB:  PubMed          Journal:  Proc Jpn Acad Ser B Phys Biol Sci        ISSN: 0386-2208            Impact factor:   3.493


  19 in total

1.  Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.

Authors:  F Bard; C Cannon; R Barbour; R L Burke; D Games; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; I Lieberburg; R Motter; M Nguyen; F Soriano; N Vasquez; K Weiss; B Welch; P Seubert; D Schenk; T Yednock
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

2.  Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease.

Authors:  H L Weiner; C A Lemere; R Maron; E T Spooner; T J Grenfell; C Mori; S Issazadeh; W W Hancock; D J Selkoe
Journal:  Ann Neurol       Date:  2000-10       Impact factor: 10.422

3.  Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization.

Authors:  J-M Orgogozo; S Gilman; J-F Dartigues; B Laurent; M Puel; L C Kirby; P Jouanny; B Dubois; L Eisner; S Flitman; B F Michel; M Boada; A Frank; C Hock
Journal:  Neurology       Date:  2003-07-08       Impact factor: 9.910

4.  Expression of amyloid-beta 1-40 and 1-42 peptides in Capsicum annum var. angulosum for oral immunization.

Authors:  Beáta Szabó; Koichi Hori; Akiko Nakajima; Noboru Sasagawa; Yuichiro Watanabe; Shoichi Ishiura
Journal:  Assay Drug Dev Technol       Date:  2004-08       Impact factor: 1.738

5.  Crude saponins improve the immune response to an oral plant-made measles vaccine.

Authors:  R J Pickering; S D Smith; R A Strugnell; S L Wesselingh; D E Webster
Journal:  Vaccine       Date:  2005-08-15       Impact factor: 3.641

Review 6.  Phytochemical studies on Ruta chalepensis (Lam.) Lamarck.

Authors:  Keriman Günaydin; Sezer Savci
Journal:  Nat Prod Res       Date:  2005-04       Impact factor: 2.861

7.  Induction of a Th2 immune response by co-administration of recombinant adenovirus vectors encoding amyloid beta-protein and GM-CSF.

Authors:  Hong-Duck Kim; Yunpeng Cao; Fan-Kun Kong; Kent R Van Kampen; Terry L Lewis; Zhendong Ma; De-chu C Tang; Ken-Ichiro Fukuchi
Journal:  Vaccine       Date:  2005-04-27       Impact factor: 3.641

8.  Nerve inflammation halts trial for Alzheimer's drug.

Authors:  Erika Check
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

9.  Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.

Authors:  D Schenk; R Barbour; W Dunn; G Gordon; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; Z Liao; I Lieberburg; R Motter; L Mutter; F Soriano; G Shopp; N Vasquez; C Vandevert; S Walker; M Wogulis; T Yednock; D Games; P Seubert
Journal:  Nature       Date:  1999-07-08       Impact factor: 49.962

10.  Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

Authors:  James A R Nicoll; David Wilkinson; Clive Holmes; Phil Steart; Hannah Markham; Roy O Weller
Journal:  Nat Med       Date:  2003-03-17       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.